1. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics. 2014. doi: 10.1007/s40273-014-0230-2 .
2. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2014. doi: 10.1007/s40273-014-0243-x .
3. Corica F, Bianchi G, Corsonello A, Mazzella N, Lattanzio F, Marchesini G. Obesity in the context of aging: quality of life considerations. Pharmacoeconomics. 2014. doi: 10.1007/s40273-014-0237-8 .
4. Li Q, Blume SW, Huang JC, Hammer M, Graf TR. The economic burden of obesity by glycemic stage in the United States. Pharmacoeconomics. 2015. doi: 10.1007/s40273-014-0248-5 .
5. Allen L, Thorpe K, Joski P. Medicare spending for obesity and selected obesity-related chronic conditions, 1987–2011. Pharmacoeconomics. 2015. doi: 10.1007/s40273-015-0284-9 .